Ranke M B, Schweizer R, Elmlinger M W, Weber K, Binder G, Schwarze C P, Wollmann H A
Paediatric Endocrinology Section, University Children's Hospital, Hoppe-Seyler Strasse 1, D-72076 Tübingen, Germany.
Horm Res. 2001;55(3):115-24. doi: 10.1159/000049982.
Little information is available on the relevance of parameters representing the insulin-like growth factor (IGF) system with regard to growth hormone (GH) treatment during childhood. In adults, high IGF-I levels were found to be associated with side effects and long-term risks.
AIM/METHOD: Our aim was to monitor the serum levels of IGF-I, IGF-binding protein (IGFBP) 3, and IGFBP-2 during long-term GH treatment of 156 patients with GH deficiency (GHD) and of 153 non-GHD patients. We determined the extent to which the IGF parameters exceed the normal ranges and identified those parameters which are predictive of 1st-year growth.
In prepubertal GHD children, the levels of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 exceeded the 95th centile of the reference values for this age group in 2.3, 0.3, and 7.9% of the cases, respectively, whereas in prepubertal non-GHD children, the same parameters exceeded the 95th reference centile in 20.1, 3.5, and 32.2%, respectively. In pubertal GHD children IGF-I, IGFBP-3, and IGF-I/IGFBP-3 levels exceeded the 95th reference centile in 11.1, 1.5, and 15.4%, respectively. In pubertal non-GHD children, these levels also exceeded the 95th centile in 26.7, 7.0, and 41.4%, respectively. In both GHD and non-GHD groups, however, some patients had IGF parameters which were below the reference values. Our analysis showed that, in both groups, in addition to maximum GH, all IGF parameters (IGF-I, IGFBP-3, IGF-I/IGFBP-3 ratio, IGFBP-2 or derivatives) significantly extend the scope of a calculated model for predicting 1st-year height velocity.
For reasons of safety and optimization of GH therapy, it is essential to follow up IGF-I, IGFBP-3, and IGFBP-2 levels regularly during childhood.
关于儿童期生长激素(GH)治疗中代表胰岛素样生长因子(IGF)系统的参数的相关性,目前可用信息较少。在成年人中,发现高IGF-I水平与副作用和长期风险相关。
目的/方法:我们的目的是监测156例生长激素缺乏症(GHD)患者和153例非GHD患者在长期GH治疗期间的血清IGF-I、IGF结合蛋白(IGFBP)3和IGFBP-2水平。我们确定了IGF参数超过正常范围的程度,并确定了那些可预测第一年生长的参数。
在青春期前的GHD儿童中,IGF-I、IGFBP-3和IGF-I/IGFBP-3水平分别在2.3%、0.3%和7.9%的病例中超过该年龄组参考值的第95百分位数,而在青春期前的非GHD儿童中,相同参数分别在20.1%、3.5%和32.2%的病例中超过第95参考百分位数。在青春期的GHD儿童中,IGF-I、IGFBP-3和IGF-I/IGFBP-3水平分别在11.1%、1.5%和15.4%的病例中超过第95参考百分位数。在青春期的非GHD儿童中,这些水平也分别在26.7%、7.0%和41.4%的病例中超过第95百分位数。然而,在GHD组和非GHD组中,一些患者的IGF参数低于参考值。我们的分析表明,在两组中,除了最大GH外,所有IGF参数(IGF-I、IGFBP-3、IGF-I/IGFBP-3比值、IGFBP-2或其衍生物)都显著扩展了预测第一年身高增长速度的计算模型的范围。
出于安全和优化GH治疗的原因,在儿童期定期随访IGF-I、IGFBP-3和IGFBP-2水平至关重要。